

April 14, 2022
CUORIPS Inc.
Asahi Intecc Co., Ltd.

Announcement of Joint Research Agreement
Regarding New Therapeutic Approach
against Cardiovascular Diseases

Tokyo, Japan (April 12, 2022) - CUORIPS (Head Office: Chuo-ku, Tokyo; President: Takayuki Kusanagi) and ASAHI INTECC Corporation (Head Office: Seto City, Aichi Prefecture; President: Masahiko Miyata) have entered into a joint research agreement to develop new therapeutic technology for transplanting allogeneic iPSC cell-derived cell product into the heart using a breakthrough approach.

CUORIPS will develop an iPSC-derived cell product suitable for the new therapeutic method by leveraging its iPSC-cell culture, differentiation, and large-scale technologies and know-how cultivated through the development of an allogeneic iPSC-derived cardiomyocyte patch, for which it has already conducted the world's first-in-human investigator-initiated clinical trial led by Osaka University.

ASAHI INTECC will establish a new cell transplantation method that will be widely used in the market by making full use of its catheter product development capabilities, which are highly regarded both domestically and internationally based on its advanced material processing technology.

Through this joint research, the two companies will contribute to future medical innovation by commercializing a new regenerative medicine/cell therapy that can be applied to the many patients suffering from cardiovascular diseases, including heart failure, which is estimated to number 1.3 million in Japan and 26 million patients worldwide.

About CUORiPS Inc.

CUORiPS Inc. is a start-up company, established in March 2017, based on technology and research results of Osaka University, for the development and commercialization of iPS cell-derived cardiomyocyte Patch and new products

CUORiPS is developing production process technology of iPS cell-derived cardiomyocyte patch to increase efficiency, and to obtain Japanese government approval as the world's 1st regenerative medicine for severe heart failures.

Asahi Intecc Co., Ltd.

Utilizing its proprietary stainless steel processing technology, the company develops, manufactures, and sells medical devices and other products centered on intravascular catheterization, including PCI guidewires used for cardiovascular catheterization, for which it has the top global market share.